Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 1
1994 4
1995 3
1996 3
1997 5
1998 2
1999 5
2000 8
2001 8
2002 8
2003 7
2004 16
2005 9
2006 9
2007 11
2008 9
2009 11
2010 12
2011 21
2012 22
2013 31
2014 36
2015 28
2016 17
2017 27
2018 33
2019 27
2020 32
2021 22
2022 22
2023 15
2024 21
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

429 results

Results by year

Filters applied: . Clear all
Page 1
Augmentation des complications sanitaires graves lors de l’usage non-médical du protoxyde d’azote en France.
Association française des centres d’addictovigilance; Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P. Association française des centres d’addictovigilance, et al. Among authors: lapeyre mestre m. Therapie. 2021 Jan-Feb;76(1):53-54. doi: 10.1016/j.therap.2020.01.001. Epub 2020 Jan 17. Therapie. 2021. PMID: 32005483 French. No abstract available.
Addictovigilance: The Edge of reason?
Lapeyre-Mestre M, Micallef J; French Addictovigilance Network; French Addictovigilance Network. Lapeyre-Mestre M, et al. Therapie. 2025 Mar-Apr;80(2):155-157. doi: 10.1016/j.therap.2025.01.001. Epub 2025 Jan 27. Therapie. 2025. PMID: 39894718 No abstract available.
Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?
Lapeyre-Mestre M, Sapède C, Moore N; les participants à la table ronde N° 5 de Giens XXVIII :; Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Therapie. 2013 Jul-Aug;68(4):241-6. doi: 10.2515/therapie/2013037. Therapie. 2013. PMID: 27392726 French. No abstract available.
Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France registry.
Moulis G, Rueter M, Duvivier A, Mahévas M, Viallard JF, Comont T, Chèze S, Audia S, Ebbo M, Terriou L, Lega JC, Jeandel PY, Hemim I, Bozzi S, Daak A, Okada H, Bonnotte B, Michel M, Lapeyre-Mestre M, Godeau B; CARMEN‐France Investigators Group. Moulis G, et al. Among authors: lapeyre mestre m. Br J Haematol. 2024 Apr;204(4):1476-1482. doi: 10.1111/bjh.19288. Epub 2024 Jan 24. Br J Haematol. 2024. PMID: 38267268
[Pharmacovigilance of self-medication].
Montastruc JL, Bagheri H, Geraud T, Lapeyre-Mestre M. Montastruc JL, et al. Among authors: lapeyre mestre m. Therapie. 1997 Mar-Apr;52(2):105-10. Therapie. 1997. PMID: 9231503 Review. French.
[Epidemiology and pharmacoepidemiology of immune thrombocytopenia].
Moulis G, Lapeyre-Mestre M, Adoue D, Sailler L. Moulis G, et al. Among authors: lapeyre mestre m. Rev Med Interne. 2017 Jul;38(7):444-449. doi: 10.1016/j.revmed.2016.12.016. Epub 2017 Jan 26. Rev Med Interne. 2017. PMID: 28131440 Review. French.
429 results